THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Inc. Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights

06/06/2022 | 08:26am EDT

Thermo Fisher Scientific Inc. is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development. The company will showcase these innovations during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022, in the Minneapolis Convention Center, Minneapolis. Enabling Next Generation Therapies to improve material quantitation and accelerate biopharma development, Thermo Fisher has added a new Thermo Scientific Direct Mass Technology mode for its Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers that lets manufacturers analyze the characteristics of biotherapeutics in greater detail throughout development. For proteomics researchers, the Thermo Scientific AccelerOme Automated Sample Preparation Platform improves reproducibility in sample prep, a longstanding bottleneck preventing wider use in biomarker discovery for disease detection and research into new therapies. A new Thermo Scientific uPAC Neo HPLC Column improves column-to-column reproducibility within proteomics and biopharmaceutical research applications as part of an end-to-end liquid chromatography-mass spectrometry (LC-MS) workflow. This further simplifies complex bottom-up proteomics analyses, enabling wider use in discovery and detection of cancer and other disease biomarkers and in development of new therapies and vaccines ranging from COVID to cancer and rare diseases. Unlocking Deeper Analytical Insights The new cloud-based Thermo Scientific Ardia platform integrates data across multiple chromatography and mass spectrometry instruments, letting biopharmaceutical and proteomics scientists share previously siloed data, simplifying analyses and unlocking deeper insights into new diagnostics and therapies that could reach the point of care sooner. New Thermo Scientific BioPharma Finder 5.1 software uses advanced algorithms to improve biotherapeutic characterization, an increasing priority as industry and regulators build stricter quality controls into the production of complex new biotherapies and vaccines. For proteomic scientists, Thermo Scientific Proteome Discoverer 3.0 software interprets data from Thermo Scientific Orbitrap mass spectrometers and applies artificial intelligence (AI), giving researchers a faster method to identify and analyze billions of possible protein interactions in humans, insights that accelerate discovery and development of next- generation drugs and vaccines. Lastly, for forensic toxicologists, clinical research toxicologists, employee drug testing facilities and wellness organizations, expanding the Thermo Scientific Tox Explorer Collection onto the Thermo Scientific Orbitrap Exploris Mass Spectrometer platform, provides an all-in-one LC-MS toxicology solution to solve complex analytical challenges and increase laboratory productivity. Cross Industry CollaborationThermo Fisher has entered a relationship with TransMIT GmbH Center for Mass Spectrometric Developments to promote a mass spectrometry imaging (MSI) platform for spatial multi-omics applications in pharmaceutical and clinical laboratories. The Thermo Scientific Orbitrap MS instrumentation, coupled with TransMIT's AP-SMALDI(5) AF Ion Source, enables higher-resolution spatial distribution mapping of cancer and other complex tissues to improve disease detection.


© S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
04:34pTHERMO FISHER SCIENTIFIC : Statement of Changes in Beneficial Ownership - Form 4
PU
08/08Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit
CI
08/05THERMO FISHER SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condit..
AQ
08/04Thermo Fisher Scientific Introduces Highly Sensitive Research Assays for Measurable Res..
CI
08/04THERMO FISHER SCIENTIFIC : Expands Cell Culture Media Manufacturing Site in Grand Island N..
PU
08/03INSIDER SELL : Thermo Fisher Scientific
MT
08/03Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution fo..
BU
08/03Thermo Fisher Scientific Inc. and Structura Biotechnology Inc. Collaborate to Offer Sol..
CI
08/01Thermo Fisher Scientific Inc. Unveils Thermo Scientific Arctis Cryo-Plasma Focused Ion ..
CI
08/01Barclays Adjusts Price Target on Thermo Fisher Scientific to $685 From $630, Reiterates..
MT
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 124 M - -
Net income 2022 6 884 M - -
Net Debt 2022 24 684 M - -
P/E ratio 2022 34,1x
Yield 2022 0,20%
Capitalization 232 B 232 B -
EV / Sales 2022 5,95x
EV / Sales 2023 5,72x
Nbr of Employees 130 000
Free-Float 88,7%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 592,35 $
Average target price 661,45 $
Spread / Average Target 11,7%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-11.22%227 578
DANAHER CORPORATION-13.30%207 497
INTUITIVE SURGICAL, INC.-35.19%83 164
EDWARDS LIFESCIENCES CORPORATION-21.70%62 887
BOSTON SCIENTIFIC CORPORATION-3.41%58 739
SIEMENS HEALTHINEERS AG-22.79%58 199